Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients (REDOXS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00133978
Recruitment Status : Completed
First Posted : August 24, 2005
Results First Posted : September 9, 2014
Last Update Posted : September 9, 2014
Fresenius Kabi
Information provided by (Responsible Party):
Daren K. Heyland, Clinical Evaluation Research Unit at Kingston General Hospital

August 22, 2005
August 24, 2005
April 29, 2013
September 9, 2014
September 9, 2014
April 2005
December 2011   (Final data collection date for primary outcome measure)
28-day Mortality [ Time Frame: Day 28 ]
28-day mortality/status: at 28 days after randomization;
The primary outcome for this study is 28-day mortality.
Complete list of historical versions of study NCT00133978 on Archive Site
  • ICU Length of Stay [ Time Frame: Day 28 ]
    Measure of the duration of participant stay in the ICU
  • ICU Acquired Infection [ Time Frame: Day 28 ]
    We have made some modifications the definitions developed by the International Sepsis Forum Consensus Conference (CCM 2005;33:1538-1548) to operationalize the adjudication of infections in this trial. We grade the certainty of the diagnosis of infection using definitions for 'Definite', 'Probable', and 'Possible' for each category of infection. The categories of infection are: Deep surgical wound infection, Incisional (or superficial) surgical wound infection, Skin and soft-tissue infection (non-surgical) (SSTS), Catheter-related blood stream infections (CRI), Primary blood stream infections (BSI), Lower urinary tract infection, Upper urinary tract infection, Intra abdominal infection, Sinusitis, Lower respiratory tract infection (excluding pneumonia), ICU Acquired Pneumonia and Other.
  • Hospital Length of Stay [ Time Frame: 6 months (from ICU admission) ]
    Measure of the duration of the participant's hospital stay
The secondary outcomes are duration of stay in ICU, adjudicated diagnosis of infection, multiple organ dysfunction, duration of mechanical ventilation, hospital length of stay, and health-related quality of life at 3 and 6 months.
Not Provided
Not Provided
Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients
REducing Deaths Due to OXidative Stress The REDOXS© Study
The purpose of this study is to determine whether providing high dose glutamine and antioxidants to critically ill patients will be associated with improved survival.


Critically ill patients experience a degree of hyperinflammation, cellular immune dysfunction, and oxidative stress. Supplementation with key nutrients, like glutamine and antioxidants, is most likely to have a favourable effect on these physiological parameters leading to an improvement in clinical outcomes. The results of two separate meta-analyses suggested that glutamine and antioxidants may be associated with improved survival. We have recently completed a dosing study to determine the maximal tolerable dose (MTD) of glutamine dipeptides and antioxidants in critically ill patients with evidence of hypoperfusion. The purpose of this protocol is to evaluate the effect of high dose glutamine and antioxidant supplementation on mortality in a large scale randomized trial.

Study Intervention:

Patients will be randomized to receive glutamine supplementation or antioxidant supplementation (or respective placebo).

Phase 3
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Critical Illness
  • Sepsis
  • Multiple Organ Failure
  • Other: Glutamine
    0.35 gm/kg/day parenterally and 30 gms/day enterally
  • Other: Antioxidants
    500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally
  • Other: Glutamine + Antioxidants
    0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg
    Other Name: Dipeptiven, Microselenium/Selenium injection/selenase, EN REDOX formula (from Fresenius Kabi, Germany)
  • Other: Placebo
    Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
  • Experimental: Glutamine
    Glutamine supplementation
    Intervention: Other: Glutamine
  • Experimental: Antioxidants
    Antioxidant supplementation
    Intervention: Other: Antioxidants
  • Experimental: Glutamine + Antioxidants
    Glutamine and antioxidant supplementation
    Intervention: Other: Glutamine + Antioxidants
  • Placebo Comparator: Placebo
    Non-isonitrogenic, iso-caloric placebo solution
    Intervention: Other: Placebo

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2012
December 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Mechanically ventilated patients > or = 18 years old
  • 2 or more organ failures related to acute illness

Exclusion Criteria:

  • > 24 hours from admission to ICU
  • Patients who are moribund
  • Lack of commitment to aggressive care
  • Absolute contraindication to enteral nutrients
  • Severe acquired brain injury
  • Routine elective cardiac surgery
  • Primary admission of burns > 30% body surface area
  • Weight < 50 kgms or > 200 kgms
  • Pregnant or lactating patients
  • Previous randomization in this study
  • Enrollment in a related ICU interventional study
  • Child's class C liver disease
  • Metastatic cancer with life expectancy < 6 months
  • Seizure disorder requiring anticonvulsant medication
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Belgium,   Canada,   Germany,   Switzerland,   United States
EudraCT-No: 2007-001831-73
Not Provided
Not Provided
Daren K. Heyland, Clinical Evaluation Research Unit at Kingston General Hospital
Daren K. Heyland
Fresenius Kabi
Study Chair: Daren Heyland, MD Clinical Evaluation Research Unit, Kingston General Hospital
Clinical Evaluation Research Unit at Kingston General Hospital
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP